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Hepatic ﬁbrosis is the result of a complex interplay between
resident hepatic cells, inﬁltrating inﬂammatory cells, and a num-
ber of locally-acting peptides called cytokines [1]. Cytokines are a
family of proteins that function as mediators of cell communica-
tion. They include chemokines, interleukins, interferons, growth
factors, angiogenic factors, vasoactive substances, soluble recep-
tors, and soluble proteases [2]. Unregulated cytokine synthesis
and release coordinate the hepatic response to injury and partic-
ipate in the initiation, progression, and maintenance of ﬁbrosis.
Over the past few years, special attention has been paid to the
role of chemokines as potential mediators and therapeutic targets
for liver ﬁbrosis. Chemokines are a group of cytokines that form a
family of small and structurally related molecules that regulate
cell trafﬁcking (chemotaxis) of various classes of leucocytes. Their
nomenclature and classiﬁcation in four groups are based on the
conﬁguration of a conserved amino-proximal cysteine-containing
motif. The CC chemokines have two juxtapositioned cysteine res-
idues, the CXC chemokines contain a non-conserved aminoacid
(X) between the two cysteine residues, the C chemokines contain
a single cysteine residue, and the CX3C chemokines contain a
non-conserved triplet of aminoacids between the two cysteine
residues. There are more than 50 ligands and 19 receptors of
the chemokine network. The CC and CXC families are the best
characterized (Fig. 1). Their function seems to be based on their
structure, as CC chemokines are, in general, chemotactic forJournal of Hepatology 20
Keywords: CXCL4; PF4; Inﬂammation; Chronic hepatitis C; Cirrhosis; Hepatic
stellate cells.
Received 3 September 2010; accepted 6 September 2010
⇑Corresponding author. Address: Liver Unit, Hospital Clinic, Villarrroel 170,
Barcelona 08015, Spain. Tel.: +34 932275400x3371; fax: +34 932275522.
E-mail address: bataller@clinic.ub.es (R. Bataller).
Abbreviations: CXCL4, chemokine (C-X-C motif) ligand 4; PF4, platelet factor 4;
CCl4, carbotetrachloride; HSC, hepatic stellate cells; MCP-1, monocyte chemo-
tactic protein 1; RANTES, regulated upon activation normal T cell expressed and
secreted; GRO, growth-regulated oncogene; IL-8, interleukin 8.mononuclear cells (monocytes and lymphocytes), whereas CXC
chemokines are important neutrophil chemoattractants and
angiogenesis inducers.
Experimental and human evidence strongly suggest that che-
mokines play an important role in acute and chronic liver dis-
eases, mediating the inﬁltration of inﬂammatory cells in the
injured liver [3]. Besides this immune action, chemokines also
regulate the biological properties of resident hepatic cells, such
as the resistance of hepatocytes to cell death and the properties
of non-parenchymal cells. In particular, chemokines are known
to stimulate pro-inﬂammatory and ﬁbrogenic actions of hepatic
stellate cells (HSC), a major cell type involved in ﬁbrogenesis.
Although the chemokine system is highly redundant and chemo-
kine receptors are promiscuous, genetic and/or pharmacological
blockade of both chemokine ligands and receptors modiﬁes the
ﬁbrogenic response to liver injury. Most chemokines studied
(i.e. MCP-1, RANTES, interleukin-8, etc.) and their receptors con-
tribute not only to the inﬁltration of inﬂammatory cells but also
to the accumulation of extracellular matrix. Because many of
these chemokines directly stimulate collagen synthesis by cul-
tured HSC, it is likely that they exert a direct proﬁbrogenic effect
in the injured liver. Moreover, chemokines released by inﬂamma-
tory cells induce hepatocellular death and can be important con-
tributors to liver failure that develop in patients with advanced
ﬁbrosis. The source of chemokines during chronic liver diseases
is not completely understood. While most studies suggest that
inﬂammatory cells are major producers of this type of cytokine,
damaged hepatocytes, activated HSC, and Kupffer cells are also
able to secrete a number of pro-inﬂammatory chemokines.
Therefore, a complex interplay between resident and inﬁltrating
cells takes place during hepatic tissue repair.
Platelets are another cell type that can release chemokines,
such as CXCL4, also known as platelet factor 4 (PF4). This plate-
let-derived chemokine promotes monocyte arrest from rolling
on the vascular wall and monocyte differentiation to macro-
phages [4]. CXCL4 is also chemotactic for neutrophils and ﬁbro-
blasts. It is stored in high micromolar concentrations in the
alpha granules of platelets and is released upon their activation.
An alternatively spliced variant of CXCR3, named CXCR3B, acts
as a functional receptor for CXCL4 [5]. In the study by Moreno
Zaldivar et al. [6], they provide evidence that CXCL4 is a plate-
let-derived factor that modulates experimentally induced liver
ﬁbrosis. In this work, the authors demonstrate that CXCL4 is
up-regulated in liver with active ﬁbrogenesis in patients with
chronic hepatitis C and non-alcoholic steatohepatitis. Impor-
tantly, the degree of expression is higher in patients with more
advanced ﬁbrosis. In mice with toxic-induced liver ﬁbrosis,11 vol. 54 j 581–583
Fig. 1. CC and CXC Chemokine ligands and their receptors. Nomenclature: GRO alpha (CXCL1), GRO beta (CXCL2), GRO gamma (CXCL3), ENA78 (epithelial-derived
neutrophil-activating peptide 78, CXCL5), GCP2 (granulocyte chemoattractant protein 2, CXCL6), NAP2 (neutrophil-activating protein 2, CXCL7), IL8 (interleukin 8, CXCL8),
MIG (monokine induced by gamma interferon, CXCL9), IP10 (interferon-gamma-induced protein 10, CXCL10), I-TAC (interferon c-inducible T cell a-chemoattractant,
CXCL11), PF4 (platelet factor 4, CXCL4), SDF1 (stromal-derived factor 1, CXCL12), BCA1 (B cell-attracting chemokine 1, CXCL13), BRAK (breast and kidney expressed
chemokine, CXCL14), Lungkine (CXCL15), SexCKine (CXCL16), Lymphotactin (XCL1), Fractalkine (CX3CL1), IL8RB (interleukin 8 receptor beta, CXCR2), IL8RA (interleukin 8
receptor alpha, CXCR1), BLR1 (Burkitt lymphoma receptor 1, CXCR5), TECK (thymus-expressed chemokine, CCL25), SLC (secondary lymphoid chemokine, CCL21), MIP3a
(macrophage inﬂammatory protein 3, liver activation regulated protein (LARC), CCL20), MIP1a (macrophage inﬂammatory protein 1), MIP1b (macrophage inﬂammatory
protein 2), RANTES (regulated upon activation normal T cell expressed and secreted, CCL5), TARC (thymus and activation-regulated chemokine, CCL17), MDC (macrophage-
derived chemokine, CCL22), MCP3 (monocyte chemoattracting protein 3, CCL7), MCP2 (monocyte chemoattracting protein 2, CCL8), Eotaxin (CCL11), HCC2 (human CC
chemokine 2, CCL15), MCP1 (monocyte chemoattracting protein 1, CCL2), MCP5 (monocyte chemoattracting protein 5, CCL12), HCC1 (human CC chemokine 1, CCL14), LEC
(liver-expressed chemokine 2, CCL16).
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CXCL4 overexpression was associated with aggregation and
activation of platelets, which accumulated in the vicinity of areas
with collagen deposition. Although a direct release of CXCL4 by
platelets was not demonstrated, their results suggest that these
cells are a potential source of CXCL4 during hepatic tissue repair.
The functional implication of CXCL4 in liver ﬁbrosis was proven
in CXCL4/ mice, which displayed reduced inﬂammation and
ﬁbrosis after carbon tetrachloride administration. In particular,
a reduced number of CD8+T cells were observed in CXCL4/
mice, suggesting a role for this chemokine in lymphocyte activa-
tion and trafﬁcking. At the cellular level, the authors provided
convincing evidence that CXCL4 induces proliferation, chemo-
taxis, and chemokine expression in activated HSC, suggesting a
direct role in the expansion of ﬁbrogenic cells.
The study by Moreno Zaldivar et al. has important physiopath-
ological implications. First, it highlights the potential role of acti-
vated platelets in liver ﬁbrogenesis. Platelets are among the ﬁrst
type of cells that are recruited in the areas of injury and are
known to release powerful ﬁbrogenic cytokines, such as trans-
forming growth factor b (TGFb) and platelet-derived growth fac-
tor (PDGF) as well as serotonin in order to favour liver
regeneration [7,8]. These actions indicate that platelet activation
plays a role in the hepatic wound healing response to injury. The
current study suggests that they may also participate in the exag-
gerated ﬁbrogenic response of the liver after repeated injury.
Because of the dual effect of platelets in promoting liver genera-
tion and ﬁbrogenesis, further studies should investigate if the
manipulation of platelet trafﬁcking and/or activation has detri-
mental or beneﬁcial effects in experimental models of acute
and chronic liver injury. Second, CXCL4 promotes blood coagula-
tion by moderating the effects of heparin-like molecules [9]. The
activation of the coagulation cascade is an important biological
event during both moderate and severe liver injury [10]. It yields
a number of activated proteases with powerful inﬂammatory
properties and it can also modulate hepatic microcirculation
leading to tissue hypoxia. This is a ‘‘hot’’ area in the ﬁeld of liver
ﬁbrosis and it is under extensive investigation. New advances areJournal of Hepatology 201anticipated in the coming years. And third, targeting CXCL4
appears to be an appealing new strategy to treat liver inﬂamma-
tion and ﬁbrosis. However, due to the diversity of the biological
actions of CXCL4 in modulating immunity and coagulation,
extensive experimental studies should ﬁrst evaluate both the
beneﬁcial and adverse effects of drugs interfering CXCL4 in
chronic liver injury.Conﬂict of interest
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